Core Viewpoint - FactSet Research reported quarterly earnings of $4.46 per share, exceeding the Zacks Consensus Estimate of $4.37 per share, and showing an increase from $4.28 per share a year ago, indicating a positive earnings surprise of +2.03% [1] Financial Performance - The company achieved revenues of $611.02 million for the quarter ended February 2026, surpassing the Zacks Consensus Estimate by 0.99% and reflecting a year-over-year increase from $570.66 million [2] - Over the last four quarters, FactSet has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - FactSet shares have declined approximately 29.5% year-to-date, compared to a 7.3% decline in the S&P 500 [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the earnings outlook for upcoming quarters [4][6] Earnings Estimates - The current consensus EPS estimate for the next quarter is $4.44, with expected revenues of $612.58 million, and for the current fiscal year, the EPS estimate is $17.42 on revenues of $2.45 billion [7] Industry Context - The Business - Information Services industry, to which FactSet belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

分组1 - LENZ Therapeutics, Inc. reported a quarterly loss of $1.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.91, and compared to a loss of $0.46 per share a year ago, indicating an earnings surprise of -28.18% [1] - The company posted revenues of $1.59 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 66.75%, and this is an increase from zero revenues a year ago [2] - LENZ Therapeutics shares have declined approximately 31.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] 分组2 - The earnings outlook for LENZ Therapeutics will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for LENZ Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.92 on revenues of $3.53 million, and for the current fiscal year, it is -$2.93 on revenues of $47.93 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which LENZ Therapeutics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting that the industry's outlook can significantly impact stock performance [8]

分组1 - Eton Pharmaceuticals reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of -58.33% [1] - The company posted revenues of $21.28 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.22%, and this is an increase from year-ago revenues of $11.65 million [2] - Eton Pharmaceuticals has topped consensus revenue estimates four times over the last four quarters [2] 分组2 - The stock has added about 12.5% since the beginning of the year, while the S&P 500 has declined by 3.2% [3] - The current consensus EPS estimate for the coming quarter is $0.20 on $21.5 million in revenues, and for the current fiscal year, it is $1.02 on $103.84 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

分组1 - DarioHealth Corp. reported a quarterly loss of $0.8 per share, which was better than the Zacks Consensus Estimate of a loss of $1.57, representing an earnings surprise of +48.88% [1] - The company posted revenues of $5.23 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.17%, but down from $7.6 million year-over-year [2] - DarioHealth shares have declined approximately 21.5% since the beginning of the year, contrasting with the S&P 500's decline of 3.2% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $5.1 million, and for the current fiscal year, it is -$3.43 on revenues of $26.8 million [7] - The Zacks Industry Rank for Medical - Instruments is in the top 36% of over 250 Zacks industries, indicating that the industry is performing relatively well [8]

Core Viewpoint - Micron reported strong quarterly earnings of $12.2 per share, significantly exceeding the Zacks Consensus Estimate of $8.8 per share, and showing a substantial increase from $1.56 per share a year ago, indicating robust performance in the semiconductor industry [1] Financial Performance - The company achieved revenues of $23.86 billion for the quarter ended February 2026, surpassing the Zacks Consensus Estimate by 21.67%, and showing a remarkable increase from $8.05 billion year-over-year [2] - Over the last four quarters, Micron has consistently exceeded consensus EPS estimates, indicating a strong operational performance [2] Stock Performance - Micron shares have increased approximately 61.8% since the beginning of the year, contrasting with a 1.9% decline in the S&P 500, showcasing the stock's strong market performance [3] Future Outlook - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $11.04 for the coming quarter and $36.18 for the current fiscal year [7] - The Zacks Rank for Micron is currently 1 (Strong Buy), suggesting that the stock is expected to outperform the market in the near future based on favorable estimate revisions [6] Industry Context - The Computer - Integrated Systems industry, to which Micron belongs, is currently ranked in the top 10% of over 250 Zacks industries, indicating a favorable environment for the company's performance [8]

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) experienced a significant stock price increase due to strong investor optimism following its robust fourth quarter financial performance [2][4]. Financial Performance - The company reported sales of $3.55 billion for the fourth quarter, reflecting a year-over-year increase of 29.3% and surpassing the Zacks Consensus Estimate by 5.9% [2]. - Adjusted EBITDA for the same period was $184 million, which is a 40.7% increase year-over-year [2]. Earnings Expectations - For the upcoming quarterly report, the company is expected to post earnings of $0.32 per share, representing a year-over-year change of +68.4% [3]. - Revenues are anticipated to reach $3.34 billion, marking a 15.9% increase from the same quarter last year [3]. Earnings Estimate Revisions - The consensus EPS estimate for the quarter has been revised 12.7% higher over the last 30 days, indicating a positive trend that typically correlates with price appreciation [4]. - Trends in earnings estimate revisions are strongly correlated with near-term stock price movements, suggesting potential strength in BTSG's stock [3][4]. Industry Context - BrightSpring Health Services, Inc. holds a Zacks Rank of 1 (Strong Buy), indicating strong market confidence in the stock [5]. - The company operates within the Zacks Medical Services industry, which includes other stocks like Medpace (MEDP), which has shown a 6% return over the past month [5].

Core Viewpoint - Sezzle Inc. (SEZL) has shown a 7.4% increase in share price over the past four weeks, closing at $68.12, with analysts suggesting a potential upside of 42.4% based on a mean price target of $97 [1]. Price Targets and Analyst Consensus - The mean estimate of $97 is derived from five short-term price targets, with a standard deviation of $10.2, indicating variability among analysts [2]. - The lowest price target of $82.00 suggests a 20.4% increase, while the highest target of $110.00 indicates a potential surge of 61.5% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about SEZL's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, four earnings estimates have been revised upward, resulting in a 7.3% increase in the Zacks Consensus Estimate [12]. Zacks Rank and Investment Potential - SEZL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14].

分组1 - The ONE Group Hospitality, Inc. reported a quarterly loss of $0.2 per share, which was worse than the Zacks Consensus Estimate of $0.26, and compared to a loss of $0.03 per share a year ago, indicating a significant earnings surprise of -176.92% [1] - The company posted revenues of $207.01 million for the quarter ended December 2025, which was in line with the Zacks Consensus Estimate but down from $221.88 million year-over-year [2] - The stock has added about 2.3% since the beginning of the year, contrasting with the S&P 500's decline of 2.5% [3] 分组2 - The earnings outlook for The ONE Group Hospitality is uncertain, with current consensus EPS estimates at $0.07 for the coming quarter and $0.43 for the current fiscal year, alongside revenues of $207.62 million and $860.06 million respectively [7] - The Zacks Industry Rank places Retail - Restaurants in the bottom 34% of over 250 Zacks industries, suggesting that the industry outlook could negatively impact stock performance [8] - The estimate revisions trend for The ONE Group Hospitality was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6]

分组1 - Adobe Systems reported quarterly earnings of $6.06 per share, exceeding the Zacks Consensus Estimate of $5.88 per share, and up from $5.08 per share a year ago, representing an earnings surprise of +3.10% [1] - The company achieved revenues of $6.4 billion for the quarter ended February 2026, surpassing the Zacks Consensus Estimate by 1.86%, and an increase from $5.71 billion year-over-year [2] - Adobe has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - Despite the positive earnings report, Adobe shares have declined approximately 21.8% since the beginning of the year, contrasting with a 1% decline in the S&P 500 [3] - The future performance of Adobe's stock will largely depend on management's commentary during the earnings call and the outlook for upcoming earnings [4][6] - The current consensus EPS estimate for the next quarter is $5.67 on revenues of $6.44 billion, and for the current fiscal year, it is $23.44 on revenues of $26.04 billion [7] 分组3 - The Computer - Software industry, to which Adobe belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Simulations Plus, is expected to report quarterly earnings of $0.27 per share, reflecting a year-over-year decline of -12.9% [9]

Core Insights - Sonida Senior Living (SNDA) reported a quarterly loss of $1.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.17, and a significant increase from a loss of $0.83 per share a year ago, indicating a negative earnings surprise of -10.26% [1] - The company generated revenues of $87.35 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 1.73% and down from $91.93 million in the same quarter last year [2] - Sonida Senior Living shares have increased by approximately 14% since the beginning of the year, contrasting with a 0.9% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.15 on revenues of $86.45 million, and for the current fiscal year, it is -$2.17 on revenues of $354.24 million [7] - The estimate revisions trend for Sonida Senior Living was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical Services industry, to which Sonida Senior Living belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The Oncology Institute, Inc., another company in the same industry, is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year change of +42.9%, with revenues anticipated to be $141 million, up 40.6% from the previous year [9][10]